ContraFect To Present at Biotech Showcase 2017 Conference

ContraFect Corporation (NASDAQ: CFRX) (NASDAQ: CFRXW), a biotechnology company focused on the discovery and development of protein and antibody therapeutics for life-threatening, drug-resistant infectious diseases, announced today that Steven C. Gilman, PhD, the Company’s Chairman and Chief Executive Officer, will present a corporate overview at the Biotech Showcase 2017 conference on Tuesday, January 10, 2017 at 9:00 AM PT (12:00 PM ET) in San Francisco, CA. The focus of the presentation will be on ContraFect’s lysin technology and its lead program, CF-301, the company’s novel approach to the treatment of drug-resistant Staphylococcus aureus (Staph aureus) infections, including MRSA.

This entry was posted in Recent Development News: Q1 - 2017, Recent Developments. Bookmark the permalink.
Read Full Article »